Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

Sai-Hong Ignatius Ou,Makoto Nishio,Myung-Ju Ahn,Tony Mok,Fabrice Barlesi,Caicun Zhou,Enriqueta Felip, Filippo de Marinis, Sang-We Kim,Maurice Pérol,Geoffrey Liu,Maria Rita Migliorino,Dong-Wan Kim,Silvia Novello,Alessandra Bearz,Pilar Garrido,Julien Mazieres, Alessandro Morabito,Huamao M Lin,Hui Yang,Huifeng Niu,Pingkuan Zhang,Edward S Kim

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer（2022）

引用 5|浏览17

暂无评分

摘要

In ALK in Lung Cancer Trial of brigAtinib-2, brigatinib was found to have a limited activity in patients with ALK+ NSCLC post-ceritinib or post-alectinib therapy. mPFS was longer with brigatinib in patients without baseline detectable plasma ALK fusion.

查看译文

关键词

Non–small cell lung cancer,Anaplastic lymphoma kinase,Tumor biomarker,Circulating tumor DNA

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要